What Can We Learn from Fragment Based Optimization Programs?
Gyorgy Keseru, Hungarian Academy of Sciences, speaking at Drug Discovery and Development 2014
Enabling New Pharma: Drug Re-purposing Efforts Go Mainstream. Innovative Alternatives for Stalled Pharmaceutical Pipelines
Rathnam Chaguturu, SRI International, speaking at Drug Discovery and Development 2014
Rising Role of Academic Drug Discovery
Barbara Slusher, Johns Hopkins University School of Medicine, speaking at Drug Discovery and Development 2014.
Webinar: How to Overcome Assay Challenges Using Custom Recombinant Antibodies
Join this webinar to find out how custom-made recombinant antibodies can solve your challenges when designing and optimizing critical assays to support drug development, diagnostic assays or discovery studies.
Science for Life Laboratory Drug Discovery & Development Platform
Per Arvidson, Karolinska Institute, speaking at Drug Discovery and Development 2014
3D Organotypic Liver Cultures and their Application in Predictive Toxicology
Fozia Noor, Saarland University, speaking at Advances in cellular Assays & Cell Culture 2014
Combining Computational Biology and High Content Imaging Approaches for Understanding DNA Damage and Repair
Thierry Dorval, AstraZeneca, speaking at High Content Analysis 2014
Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
Christine Dufes, University of Strathclyde, speaking at Nanomedicine 2014.
Nanomedicines to Improve the Therapeutic Index of Drugs in Modern Drug Design
Marianne Ashford, AstraZeneca, speaking at Nanomedicine 2014.
Using In vitro and In vivo Models to Assess the Local and Systemic Responses to Nanomaterial Exposure
Vicki Stone, Heriot-Watt University, speaking at Nanomedicine 2014.
|<<|| 1 2 3 4 5 6 7 || >>|
|Showing Results 1 - 10 of 102|